Annals of Oncology 6:559-567, 1995
© 1995 European Society for Medical Oncology
research-article |
Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases
1ICRF Department of Medical Oncology, St. Bartholomew's Hospital London, England, U.K
2Department of Histopathology, St. Bartholomew's Hospital London, England, U.K
Correspondence to: Professor T. Andrew Lister, M.D., FRCP, FRCPath., ICRF Department of Medical Oncology, 45 Little Britian, St. Bartholomew's Hospital, West Smithfield, London ECIA 7BE, England, U.K.
BACKGROUND: Lymphocyte predominant Hodgkin's disease (LP-HD), particularly that with a nodular pattern has been suggested to constitute a distinct disorder within the spectrum of Hodgkin's disease, this issue being based on clinical, morphological and immunological observations. Furthermore, the nodular LP-HD (N-LP-HD) has been considered to differ from the diffuse subtype (D-LP-HD), although the data are conflicting. The question addressed in this study was whether the clinical course of N-LP-HD differs from that of the D-LP-HD as well as the other subtypes of Hodgkin's disease.
PATIENTS AND METHODS: 90 cases diagnosed as LP-HD at St. Bartholomew's Hospital (SBH) were reviewed. The histo-pathological classification was based on the original Lukes and Butler criteria for classical N-LP-HD. Clinical data were retrieved from case notes and a computer database. Stage was determined by the Ann Arbor criteria. Survival and remission duration analyses were performed for the group of patients with N-LP-HD and compared with an histological control group of patients with the other subtypes of Hodgkin's disease and the cases of LP-HD that have been reclassified.
RESULTS: 1. 50/90 cases (56%) originally diagnosed as N-LP-HD qualified as N-LP-HD. No case with the diffuse subtype, could be identified. Twenty-three percent of the cases were reclassified as Mixed Cellularity and 11% as Nodular Sclerosis HD, whilst 10% as non-Hodgkin's lymphomas.
2. The majority of cases (78%) presented with early stage(I plus; II). Bone marrow and liver involvement were rare.
3. 92% of cases achieved complete remission. Recur-rence developed in only 6/46 patients within 5–12 years. A second complete remission was achieved in 5/6 (83%) cases. Further recurrences have not yet occurred.
4. The overall survival of the 50 cases with N-LP-HD was 92% at 4 years and did not differ significantly from the 40 cases that have been reclassified. Remission duration however, was significantly better for the group of N-LP-HD being 81% at 12 years.
5. Second malignancies were common and developed in 6/50 cases (12%) with N-LP-HD within 10–15 years. These included: ALL (1 case), high grade B-NHL (2 cases), squa-mous cell carcinoma (1 case), glioma (1 case), lung carcinoma (1 case).
6. 12/50 patients died within a period of follow-up, up to 21 years. 1/3 of the deaths was attributed to the development of second malignancy.
CONCLUSIONS: The diffuse variant of LP-HD is rare, having not been seen at St. Bartholomew's Hospital during this time period. The 50 cases with N-LP-HD showed a favourable course with presentation at an early stage, good response to treatment, late recurrences and remission duration significantly longer than the other subtypes of HD. The latter could be attributable to the early stage at presentation of N-LP-HD, since the remission duration on a matching on stage analysis was superficially better in favour of N-LP-HD (p 
0.06). The indolent course of the disease in combination with the risk of second malignancy cases raises the question whether histology should be taken into consideration in the development of new protocols for HD.
Hodgkin's disease, lymphocyte predominant, nodular type of lymphocyte predominant, diffuse type of lymphocyte predominant, L + H cells
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. I. Lee and A. S. LaCasce Nodular Lymphocyte Predominant Hodgkin Lymphoma Oncologist, July 1, 2009; 14(7): 739 - 751. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nogova, T. Reineke, C. Brillant, M. Sieniawski, T. Rudiger, A. Josting, H. Bredenfeld, R. Skripnitchenko, R.-P. Muller, H.-K. Muller-Hermelink, et al. Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group J. Clin. Oncol., January 20, 2008; 26(3): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nogova, T. Rudiger, and A. Engert Biology, Clinical Course and Management of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Hematology, January 1, 2006; 2006(1): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nogova, T. Reineke, H. T. Eich, A. Josting, H. K. Muller-Hermelink, K. Wingbermuhle, C. Brillant, A. Gossmann, J. Oertel, M. V. Bollen, et al. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG) Ann. Onc., October 1, 2005; 16(10): 1683 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pellegrino, M.J. Terrier-Lacombe, O. Oberlin, T. Leblanc, Y. Perel, Y. Bertrand, C. Beard, C. Edan, C. Schmitt, D. Plantaz, et al. Lymphocyte-Predominant Hodgkin's Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection--A Study of the French Society of Pediatric Oncology J. Clin. Oncol., August 1, 2003; 21(15): 2948 - 2952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Connors, E. M. Noordijk, and S. J. Horning Hodgkin's Lymphoma: Basing the Treatment on the Evidence Hematology, January 1, 2001; 2001(1): 178 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Aster Lymphocyte-Predominant Hodgkin's Disease: How Little Therapy Is Enough? J. Clin. Oncol., March 1, 1999; 17(3): 744 - 744. [Full Text] [PDF]
|
|
|
|
|
|
V. Diehl, M. Sextro, J. Franklin, M.-L. Hansmann, N. Harris, E. Jaffe, S. Poppema, M. Harris, K. Franssila, J. van Krieken, et al. Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease J. Clin. Oncol., March 1, 1999; 17(3): 776 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Chhanabhai, S. Krajewski, M. Krajewska, H.-G. Wang, J. C. Reed, and R. D. Gascoyne Immunohistochemical Analysis of Interleukin-1beta -Converting Enzyme/Ced-3 Family Protease, CPP32/Yama/Caspase-3, in Hodgkin's Disease Blood, September 15, 1997; 90(6): 2451 - 2455. [Abstract] [Full Text] [PDF]
|
|